Clinical stages included were III (1.6%), IV (78.7%), and recurrence after surgical resection (19.7%). Most patients, 52.5%, had an ECOG status of 0 and 100% of patients had a histopathological diagnosis of adenocarcinoma.
![free age progression free age progression](https://images.medicaldaily.com/sites/medicaldaily.com/files/2014/04/11/ageprogression.png)
In the combination arm, the median age was 67 years (range, 41-86), 60.7% were female, and 37.7% had a smoking history. Fifty-nine percent of patients had an exon 19 deletion and 41% had a Leu858Argmutation. Clinical stages included were III (3.3%), IV (75.4%), and recurrence after surgical resection (21.3%). Most patients, 55.7%, had an ECOG score of 0 and 98.4% had a diagnosis of adenocarcinoma. The median age of patients in the monotherapy arm was 66 years (range, 29-85), 62.3% were female, and 50.8% of patients had a smoking history. At the time off data cutoff, 20 patients remained on study treatment. In the combination arm, all patients received treatment and all 62 were evaluable. At data cutoff, 17 patients in this arm remained on study treatment. In the monotherapy arm, 60 patients went on to treatment and 58 were evaluable. Sixty-one patients were assigned to each arm. Stratification factors included clinical stage, sex, exon 19 deletion, and L858R mutation.
#Free age progression plus
Patients were randomized 1:1 to receive either osimertinib (80mg, daily) plus bevacizumab (15mg/kg, once every 3 weeks) or osimertinib (80mg, daily) alone. Secondary end points include overall response rate (ORR), overall survival (OS), and adverse events (AEs). The primary end point of the study is PFS. Patients with symptomatic brain metastases were also excluded. All patients were previously untreated, had clinical stage IIIB, IIIC, IV, or recurrent disease after surgical resection, and ECOG score of 0 or 1, and at least 20 years of age.
![free age progression free age progression](https://ageprogression.files.wordpress.com/2010/09/hollyx2-adjusted.jpg)
The phase 2 WJOG917L study, which was conducted in Japan, enrolled 122 patients with EGFR-mutated NSCLC.